{"organizations": [], "uuid": "debcf60bc370b1fcc1f8c17027fdf9d64ddc1bb2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180221.html", "section_title": "Archive News &amp; Video for Wednesday, 21 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-genmab-2017-operating-profit-beats/brief-genmab-2017-operating-profit-beats-expectations-idUSNASM000JK", "country": "US", "domain_rank": 408, "title": "BRIEF-Genmab ‍2017 Operating Profit Beats Expectations", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-22T00:20:00.000+02:00", "replies_count": 0, "uuid": "debcf60bc370b1fcc1f8c17027fdf9d64ddc1bb2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-genmab-2017-operating-profit-beats/brief-genmab-2017-operating-profit-beats-expectations-idUSNASM000JK", "ord_in_thread": 0, "title": "BRIEF-Genmab ‍2017 Operating Profit Beats Expectations", "locations": [], "entities": {"persons": [{"name": "genmab", "sentiment": "negative"}, {"name": "jacob gronholt-pedersen", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "novartis", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 21 (Reuters) - GENMAB:\n* ‍REVENUE WAS DKK 2,365 MILLION IN 2017 * ‍OPERATING EXPENSES DKK 1,021 MLN IN 2017​ * ‍OPERATING INCOME WAS DKK 1,344 MLN IN 2017​ * SEES 2018 REVENUE AT DKK ‍2,700 - 3,100​ MLN\n* SEES 2018 OPERATING EXPENSES AT DKK 1,400-1,600 MLN​\n* SEES 2018 ‍OPERATING INCOME AT DKK 1,300-1,500​ MLN\n* ‍PROJECTED REVENUE FOR 2018 CONSISTS PRIMARILY OF DARZALEX ROYALTIES OF APPROXIMATELY DKK 1,750 MLN THAT ARE BASED ON AN ESTIMATED USD 2.0 - 2.3 BLN OF DARZALEX NET SALES IN 2018​\n* ‍PROJECTS DARZALEX MILESTONES OF APPROXIMATELY DKK 550 MLN IN 2018​\n* ‍2018 GUIDANCE INCLUDES ONE-TIME PAYMENT FROM NOVARTIS OF APPROXIMATELY DKK 300 MLN​​ SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Reporting by Jacob Gronholt-Pedersen)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-22T00:20:00.000+02:00", "crawled": "2018-02-22T17:48:10.018+02:00", "highlightTitle": ""}